Stanford study investigating the role of human exposome in Crohn’s disease using wearable sensors and multiomics profiling

by Stanford Healthcare Innovation Team | Aug 4, 2022 | Research Study, Volunteers Needed

We are conducting a study to better understand the association between airborne exposures and onset and flares of Crohn’s disease. Click here to learn more about the study and enroll if eligible. What is the Exposome? Exposome refers to the measure of all the...

We want to understand long-term impacts of COVID-19 on your physical and mental health

by Stanford Healthcare Innovation Team | Aug 3, 2022 | Research Study, Survey

Stanford University is partnering with Intrivo On/Go to better understand what types of health conditions or “comorbidities” are associated with COVID-19. We are also gathering information on mental health and resources you can access during the pandemic. Your data is...

Behind the Research: Precision environmental health monitoring by longitudinal exposome and multi-omics profiling

by Stanford Healthcare Innovation Team | Jun 23, 2022 | New Publication, Precision Medicine, Research

In Conversation with Peng Gao Peng Gao is an assistant professor at The University of Pittsburgh’s School of Public Health and was formerly a postdoctoral fellow in The Snyder Lab at Stanford University School of Medicine. Peng’s most recent paper...

Personalized Medicine, Big Data, and AI Summer Workshop

by Stanford Healthcare Innovation Team | Jun 3, 2022 | Education Opportunity

Calling all future researchers, bioinformaticians, healthcare entrepreneurs, and future medical practitioners.Wondering how to get started in the rapidly expanding field of personalized medicine and healthcare innovation? Look no further than The Personalized...

A cancer-associated RNA polymerase III identity drives robust transcription and expression of snaR-A noncoding RNA

by Stanford Healthcare Innovation Team | May 31, 2022 | News, Research, Research Study

Upregulation of POLR3G, which is driven by MYC, identifies a subgroup of patients with unfavorable survival outcomes in specific cancers,further implicating the POLR3G-enhanced transcription repertoire as a potential disease factor. Read a summary of this paper below...